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Background: Chronic inflammation is related to both obesity and diabetes. Our aim was to investigate to what
extent this inflammation contributes to the association between obesity and diabetes.
Methods: Using a case-cohort design, we followed 567 middle-aged individuals who developed diabetes and 554
who did not over 9 years within the ARIC Study. Weighted Cox proportional hazards analyses permitted statistical
inference to the entire cohort.
Results: Obese individuals (BMI≥30 kg/m2), compared to those with BMI<25 kg/m2, presented a large increased
risk of developing diabetes (HR[obesity]=6.4, 95%CI 4.5–9.2), as did those in the highest (compared to the lowest)
quartile of waist circumference (HR[waist]=8.3, 95%CI 5.6–12.3), in analyses adjusted for age, gender, ethnicity, study
center, and parental history of diabetes. Notably, further adjustment for adiponectin and inflammation markers
halved the magnitude of these associations (HR[obesity]=3.2, 95%CI 2.1–4.7; and HR[waist]=4.2, 95%CI 2.8–6.5). In
similar modeling, attenuation obtained by adding fasting insulin, instead of these markers, was only slightly more
pronounced HR[obesity]=2.7, 95%CI 1.7–4.1; and HR[waist]=3.6, 95%CI 2.3–5.8).
Conclusions: The marked decrease in the obesity-diabetes association after taking into account inflammation markers
and adipokines indicates their major role in the pathways leading to adult onset of diabetes in obese individuals.
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Diabetes is a health problem of increasing concern. The
World Health Organization estimates that 2.9 million
deaths per year are attributable to diabetes, and this num-
ber is likely to increase by more than 50% in the next dec-
ade [1]. Much of this burden may be explained by the
dramatic rise in obesity rates [2]. It is well established that
obesity is one of the strongest risk factors for diabetes,
but causal mechanisms for this relationship are not fully
established [3].
Obesity has been shown to lead to functional and mor-
phological damage to remote tissues via circulating factors
[3-5]. Hotasmiligil first proposed, in 1994, that inflam-
mation is a key component of the obesity-diabetes link
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reproduction in any medium, provided the orstudy, we demonstrated that a mild state of inflamma-
tion precedes and predicts type 2 diabetes, independ-
ently of other risk factors, including obesity [7]. The last
decade has witnessed a considerable number of investi-
gations in humans and animals to support the role of in-
flammation and adipokines in the development of diabetes
[8]. However, to our knowledge, to what degree inflamma-
tory processes and insulin resistance contribute to the asso-
ciation of obesity and diabetes has not been evaluated in an
epidemiologic context.
The ARIC study offers a unique opportunity to examine
this through a case-cohort study rich in measurements
of inflammation markers and adipokines. Thus, we investi-
gated the possible role of inflammatory processes, as indi-
cated by biomarkers, and adipokines in the obesity-diabetes
association, by quantifying the degree of reduction in the
strength of the obesity-diabetes association when taking
these factors into account.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Subjects
Between 1987 and 1989 the Atherosclerosis Risk in Com-
munities (ARIC) study recruited a population-based co-
hort of 15,792 men and women aged 45–64 years from
four US communities. In the present analyses, we used a
case-cohort design, as previously described in the investi-
gation of the role of several inflammation biomarkers in
the development of diabetes in the ARIC study [9-11].
Prior to sampling, we excluded 2,018 participants with
prevalent diabetes, 95 members of minority ethnic groups
with small numbers, 853 individuals who did not return
to any follow-up visit, 26 with no valid diabetes determin-
ation at follow-ups, 7 with restrictions on stored plasma
use, 12 with missing baseline anthropometric measure-
ments, and 2,506 participants in previous ARIC case–
control and case-cohort studies involving cardiovascular
disease for whom stored plasma was either previously ex-
hausted or held in reserve. We selected ethnicity-stratified
(50% white, 50% African-American) random samples of
both cases of incident diabetes and members of the full
ARIC cohort not presenting diabetes at baseline, resulting
in 1198 individuals. We then additionally excluded 45 par-
ticipants with incomplete fasting (<8 h) and 32 not having
values for inflammation markers or non-esterified fatty
acids. Our final sample was 567 diabetes cases and 554
non-cases. A few of the incident cases of diabetes over-
lapped with and some were selected only via the cohort
random sample (n = 650). Cases were defined on the basis
of a reported physician diagnosis, reported use of anti-
diabetic medications, or a fasting glucose value ≥7.0 mmol/l,
at any of the 3 follow-up visits, each occurring approxi-
mately 3 years after the previous. The date of diabetes inci-
dence was estimated by linear interpolation using glucose
values at the ascertaining visit and the prior one, as previ-
ously described [9]. Non-cases were followed for a median
of 9 years, and incident cases were followed until the onset
of diabetes (median = 3 years). Human-subject research
review committee at the Hospital de Clínicas de Porto
Alegre approved this study, and all participants gave writ-
ten informed consent.Measurements
We measured waist girth at the umbilical level and hip
circumference at the maximum hip girth in order to ob-
tain the waist-to-hip ratio, and divided weight by height
squared to obtain the body mass index (BMI). Individuals
presenting BMI ≥ 30 kg/m2 were classified as obese, those
presenting a BMI value equal or greater than 25 but lower
than 30 kg/m2 were classified as overweight, and those with
BMI < 25 kg/m2 (including 2 individuals < 18.5 kg/m2)
were considered as having normal body weight. In order to
assess the association of waist circumference values withincidence of diabetes, we also compared waist circumfer-
ence extreme quartiles.
We defined parental history of diabetes as a report of
diabetes in either parent, and hypertension as sitting
blood pressure of 140/90 mm Hg or more or use of
antihypertension medication.
We used a score [9], ranging from 0 to 6, to indicate
low-grade systemic inflammation, attributing 1 point for
a value greater than the median of the cohort sample for
each of the six inflammation markers: IL-6, C-reactive
protein, orosomucoid, sialic acid, white cell count and fi-
brinogen. Laboratory measurements and reliability coeffi-
cients for these measurements are described in previous
reports [9-12]. Complement component 3 was measured
by immunoturbidimetric assay, with reliability coefficient
of 0.67.
Statistical analysis
We used weighted Spearman correlations to describe crude
associations between BMI and waist circumference and
other variables, and weighted ANCOVA to compute ad-
justed BMI means in diabetes cases and non-cases. We
performed Cox proportional hazards regressions to analyze
the relation between BMI and time to onset of diabetes,
with appropriate weighting for the stratified sample selec-
tion. In these analyses, weights are defined as the inverse
of the ethnicity-specific sampling fractions. Leptin quartiles
were defined in a sex-specific manner [11]. Adiponectin,
C3, oxidized LDL, ICAM-1 and other continuous variables
were centered in their means, in order to avoid multi-
collinearity. Centering was performed subtracting from each
observed value the mean of the variable in question and
then dividing the difference by the standard deviation of the
variable’s distribution: (observed – mean) / standard devi-
ation. Thus, values of continuous variables are expressed as
standard deviations from the mean. To test heterogeneity in
the obesity–incident diabetes association across categories
of covariates of ethnicity (African American vs. white) and
smoking (current vs. former vs. never), shown in previous
analyses to modify the association between inflammation
markers and diabetes [9], we employed a test of interaction.
Statistical analyses were performed using the SAS (SAS
Institute Inc., Cary, NC) and SUDAAN (Research Triangle
Institute, Raleigh, NC) statistical software packages, based
on the case-cohort sampling design. The proportional haz-
ards assumption was examined through plots of Martingale
and Schoenfeld residuals [13]. Collinearity across independ-
ent variables was investigated with linear regression models:
variance inflation factors were < 2.5 in BMI models, < 4.5
in waist models and < 3.5 in insulin models.
Results
Characteristics of cases and non-cases have previously
been reported [11]. In brief, the cohort was made up of
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teria, 31% of the individuals of the cohort random sam-
ple (n=650) were at normal body weight (18.5 < BMI <
25 kg/m2), 41% were overweight (25 ≤ BMI < 30 kg/m2)
and 28% were obese (BMI ≥ 30 kg/m2) at baseline. BMI
mean values were 26.9 (95%CI: 26.4–27.5) for men, 26.8
(95%CI 26.4–27.4) kg/m2 for women, and were higher
in African-Americans (28.8, 95%CI 28.1–29.5 kg/m2) than
whites (26.4, 95%CI 25.9–26.9 kg/m2). According to the
criteria of the Third Report of the National Cholesterol
Education Program (NCEP) criteria [14], 52% of the indi-
viduals in the cohort random sample presented abdominal
obesity at baseline (waist circumference >102 cm for men
and >88 cm for women). In this population, the highest
quartile of waist circumference was >102 cm in men
and >101 cm in women, and the first quartile of waist cir-
cumference was <91 cm in men and <84 cm in women.Table 1 Spearman correlations for obesity with inflammatio
sample (n=650)
BMI
r P-value
Main exposure variables
BMI
Waist 0.83 <0.01
Insulin 0.55 <0.01
Inflammation markers and adipokines
Adiponectin, in men −0.23 <0.01
Adiponectin, in women −0.31 <0.01
C-reactive protein 0.40 <0.01
IL-6 0.29 <0.01
Fibrinogen 0.24 <0.01
Orosomucoid 0.32 <0.01
Sialic acid 0.19 <0.01
White blood count 0.07 <0.01
Complement component 3 0.43 <0.01
Oxidized LDL 0.06 0.12
ICAM-1 (ng/mL) 0.04 0.36
Leptin, in men 0.64 <0.01
Leptin, in women 0.73 <0.01
Other metabolic variables
Non-esterified fatty acids 0.07 0.07
Systolic blood pressure 0.24 <0.01
Diastolic blood pressure 0.21 <0.01
Triglycerides 0.21 <0.01
HDL-cholesterol, in men −0.18 0.01
HDL-cholesterol, in women −0.28 <0.01
HOMA-IR 0.55 <0.01
Fasting glucose 0.26 <0.01Spearman correlations, assessed in the cohort random
sample (Table 1), show that BMI, waist circumference and
serum insulin levels were associated with virtually all of the
inflammation markers and adipokines. Correlations were
frequently of the magnitude seen for metabolic factors.
Table 2 shows progressive parallel models for diabetes,
considering obesity and overweight (according to BMI,
both categories in the same model), waist circumference
and fasting insulin as main exposure variables. Obesity,
compared to normal body weight, was a strong risk factor
for diabetes (HR=6.4, 95%CI 4.5–9.2), adjusted for age,
gender, ethnicity, study center, and parental history of dia-
betes. Inclusion of adiponectin and then other adipokines
and inflammation markers greatly reduced the magnitude
of the association (HR=4.7, 95%CI 3.2–6.8 and 3.2, 95%CI
2.1–4.7, respectively). A similar pattern of associations was
seen when overweight (25 kg/m2 ≤ BMI < 30 kg/m2) andn and metabolic variables in the cohort random
Waist Insulin
r P-value r P-value
0.83 <0.01 0.55 <0.01
0.53 <0.01
0.53 <0.01
−0.25 <0.01 −0.30 <0.01
−0.29 <0.01 −0.46 <0.01
0.36 <0.01 0.35 <0.01
0.32 <0.01 0.19 <0.01
0.22 <0.01 0.20 <0.01
0.33 <0.01 0.31 <0.01
0.16 <0.01 0.11 0.01
0.14 <0.01 0.10 <0.01
0.39 <0.01 0.46 0.06
0.10 0.01 0.07 0.06
0.12 <0.01 0.10 0.01
0.65 <0.01 0.50 <0.01
0.69 <0.01 0.65 <0.01
0.04 0.31 −0.01 0.75
0.24 <0.01 0.33 <0.01
0.20 <0.01 0.27 <0.01
0.28 <0.01 0.30 <0.01
−0.26 <0.01 −0.28 <0.01
−0.32 <0.01 −0.36 <0.01
0.53 <0.01 0.99 <0.01
0.30 <0.01 0.44 <0.01
Table 2 Hazards ratios for diabetes according to obesity and insulin levels, considering possible mediators
and confounders
Main exposure
Overweight a Obesity b Waist circumference 4th quartile c Insulin 4th quartile d
HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI)
Model 1 2.07 (1.45–2.95) 6.43 (4.48–9.21) 8.30 (5.60–12.28) 10.71 (6.20–18.51)
Model 2 1.72 (1.20–2.48) 4.69 (3.23–6.81) 6.27 (4.18–9.40) 6.90 (3.87–12.32)
Model 3 1.45 (1.00–2.11) 3.18 (2.14–4.73) 4.23 (2.76–6.49) 4.44 (2.45–8.04)
Model 4 1.46 (0.98–2.17) 3.21 (2.01–5.14) 5.08 (2.97–8.71) 4.56 (2.38–8.73)
Model 5 1.17 (0.78–1.76) 2.26 (1.37–3.73) 3.19 (1.58–6.45) 3.42 (1.75–6.71)
Model 1: Adjusted for age, study center, ethnicity, gender, and family history of diabetes.
Model 2: Model 1 + adiponectin.
Model 3: Model 2 + inflammation score, C3; oxidized LDL, ICAM-1.
Model 4: Model 3 + leptin (gender-specific quartiles).
Model 5: Model 4 + hypertension, non-esterified fatty acids, ln-triglycerides, ln-triglycerides2, HDL-cholesterol, BMI, BMI2, waist-to-hip ratio,
ln-insulin (those not already in the model).
a Hazards ratio of overweight (25 kg/m2 ≤ BMI < 30 kg/m2) versus BMI < 25 kg/m2.
b Hazards ratio of obese (BMI ≥ 30 kg/m2) versus BMI < 25 kg/m2.
c 4th vs. 1st quartile. In men: waist circumference >102 cm vs. <91 cm; in women: waist circumference >101 cm vs. <84 cm.
d 4th vs. 1st quartile: >13 μu/mL vs. < 5 μu/mL.
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Although the same pattern was also observed when
fasting insulin was the main exposure, the minimally ad-
justed hazard ratio was somewhat larger and the reduction
with adiponectin adjustment, more pronounced. After
including the adipokine leptin in these analyses, the as-
sociation increased slightly, particularly so in the waist
circumference analysis. When additionally adjusting for
hypertension and other variables associated with the meta-
bolic syndrome, associations were further reduced.
As insulin resistance is considered a central mechanism
in the causation of type 2 diabetes, we performed similar
models of progressive adjustment, but adding insulin prior
to adiponectin and inflammation markers. As seen inTable 3 Hazards ratios for diabetes according to obesity leve
Overweight a O
HR (95%CI) H
Model 1 2.07 (1.45–2.95) 6.4
Model 1’ 1.27 (0.87–1.86 2.6
Model 2 1.23 (0.84–1.81) 2.5
Model 3 1.09 (0.74–1.60) 1.8
Model 4 1.29 (0.86–1.94) 2.4
Model 5 1.17 (0.78–1.76) 2.2
Model 1: Adjusted for age, study center, ethnicity, gender, and family history of dia
Model 1’: Model 1 + ln-insulin.
Model 2: Model 1’ + adiponectin.
Model 3: Model 2 + inflammation score, C3; oxidized LDL, ICAM-1.
Model 4: Model 3 + leptin (gender-specific quartiles).
Model 5: Model 4 + hypertension, non-esterified fatty acids, ln-triglycerides, ln-trigly
a Hazards ratio of overweight (25 kg/m2 ≤ BMI < 30 kg/m2) versus BMI < 25 kg/m2.
b Hazards ratio of obese (BMI ≥ 30 kg/m2) versus BMI < 25 kg/m2.
c 4th vs. 1st quartile. In men: waist circumference >102 cm vs. <91 cm; in women: wTable 3, insulin adjustment markedly decreased the size
of the obesity-diabetes association. Nonetheless, further
adjustment for adiponectin and inflammation markers
led to additional large decreases – HR[obesity] from 2.7,
1.7–4.1 to 1.8, 1.2–2.9 and HR[waist circumference] from
3.6, 2.3–5.8 to 2.5, 1.6–4.1). Adjustment with the HOMA-
IR measure, instead of insulin, produced quite similar
results (data not shown). In these analyses, adjustment
for leptin also resulted in a notable increase in the main
associations, particularly when waist circumference was
analyzed.
No heterogeneity in the pattern of these associations
was observed across categories of ethnicity or smoking.
A secondary analysis, excluding 27 individuals originallyls, adjusting for insulin prior to inflammation markers
Main exposure
besity b Waist circumference 4th quartile c
R (95%CI) HR (95%CI)
3 (4.48–9.21) 8.30 (5.60–12.28)
7 (1.73–4.13) 3.63 (2.28–5.78)
1 (1.63–3.88) 3.43 (2.16–5.46)
5 (1.20–2.86) 2.54 (1.58–4.08)
8 (1.52–4.05) 4.10 (2.34–7.20)
6 (1.37–3.73) 3.19 (1.58–6.45)
betes.
cerides2, HDL, BMI, BMI2, waist-to-hip ratio, (those not already in the model).
aist circumference >101 cm vs. <84 cm.
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glucose load of ≥11.1 mmol/L at ARIC Visit 4, produced
similar results (data not shown).Discussion
In this middle-age population, obese individuals had a
more than 6-fold higher risk of developing diabetes of
those with BMI less than 25 kg/m2 in models adjusting for
age, gender, center, ethnicity, and parental history of dia-
betes. However, once additional adjustment for adiponectin
and inflammation markers was performed, the relative
excess risk (1-HR), the measure which best permits
comparison of the strength of the main exposure associ-
ations following different adjustments, dropped by more
than 50%. Similar results were observed when waist cir-
cumference and fasting insulin were considered in the
models instead of obesity (Table 2). The extent of the
reductions seen with adiponectin and inflammation
markers was nearly as large as that seen with fasting in-
sulin (Table 3), a surrogate measure of insulin resist-
ance, which is recognized as a major proximal cause of
type 2 diabetes.
Obesity has long been considered the major risk factor
for the development of diabetes. However, how it exerts
its effect has only relatively recently been investigated with
robust basic science models, for example, those involv-
ing gene knock-out [4]. Once thought to be merely an
energy storage site, adipose tissue is now considered the
body´s largest endocrine organ, producing a wide var-
iety of intercellular signaling molecules – the so-called
adipokines.
Adiponectin is the one of the most expressed of these
molecules. Adiponectin has multiple functions, including
up-regulation of AMPK, which stimulate glucose uptake
into tissue and minimizes liver gluconeogenesis. Add-
itionally, adiponectin has anti-inflammatory and insulin-
sensitizing effects [15]. In this community-based sample
of U.S. adults [10] and now in many others [16], higher
adiponectin levels were associated with a lower incidence
of diabetes. With increase in adiposity, adiponectin levels
fall. Thus, the marked decrease in risk seen with addition
of this adipokine to the model may be explained, at least
in part, as mediation of the obesity effect.
Studies investigating various markers of inflammation
in different populations have now confirmed our initial
demonstration that a low-grade inflammation precedes and
predicts diabetes development in middle-age adults [8].
Given the multiple pathways involved in inflammatory pro-
cesses and the lack of a clear role for specific biomarkers in
diabetes etiology, we employed here an inflammation score
composed by 6 different markers, as utilized in previous
ARIC studies [9]: a mix of a cytokine, four acute-phase re-
actants, and the leukocyte count. Additionally, we adjustedfor other inflammation markers measured more recently in
this sample.
How molecular mediators of inflammation might cause
diabetes is still open to speculation. We have worked within
a conceptual framework based on the necessity, throughout
evolution, of growth, development, reproduction on the
one hand, and bodily defense for survival, on the other,
coupled with the concept that the same internal machinery
must adapt to serve these different needs at different times.
Thus, metabolism is altered depending on sensed neces-
sities. Within this theory, when the perceived need is
growth, development and reproduction, insulin is a key
signal. However, when the need is for bodily defense, as
signaled by inflammation mediators, metabolism is restruc-
tured, and insulin resistance is utilized to minimize energy
use in the above-mentioned functions. When inflamma-
tion becomes chronic, as seen in obesity, it induces
chronic restructuring of metabolic pathways. In fact, mul-
tiple effects of inflammation mediators on metabolic pa-
rameters which are altered in the progression from obesity
to type 2 diabetes have been documented [3,17]. Addition-
ally, adipokine-induced endothelial dysfunction of nutri-
tive vascular beds with subsequent insulin resistance has
been postulated [4], perhaps explaining why hypertension
and markers of endothelial dysfunction, including those of
microvascular circulation [18] have been found to predict
the development of diabetes.
Whether the reduction of the association between
obesity and type 2 diabetes found with adjustment for
inflammation markers is due to mediation or confounding
by inflammation cannot be established within our dataset.
To a certain extent, it is probably due to both.
In favor of mediation is the fact that obesity is clearly a
pro-inflammatory state (obesitis), with changes in adipo-
cyte gene expression and with infiltration of inflammatory
cells, most notably macrophages [19] into adipose tissue.
Many inflammation markers are produced by activated
adipocytes and/or in activated adipose tissue – IL-6, C-
reactive protein and complement component C3 being
among those that we have analyzed here. Signals gener-
ated in adipose tissue, both adipokines and other inflam-
matory molecules, then lead to striking rises in a series of
plasma proteins synthesized by the liver (as fibrinogen and
orosomucoid) [9].
However, we [20] and others [21] have shown that low
grade chronic inflammation is a strong predictor of weight
gain, which argues rather, at least in part, for confounding,
in which inflammation would be a common cause of both
obesity, and through a separate mechanism, type 2 diabetes.
A possible mechanism explaining this confounding is
chronic excess, food intake, particularly of pro-inflammatory
foodstuffs [22]. Excess food intake goes hand in hand with
the development and maintenance of obesity, and excess
consumption was shown to be pro-inflammatory [23].
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reticulum (ER) is a major site for intracellular protein,
lipid and sterol synthesis. In balancing intracellular sup-
ply and demand in the process of constructing new mol-
ecules, the ER has now been shown to be also a major
generator of metabolic and inflammatory signals. ER stress
is an early consequence of nutrient excess and a cause for
the development of inflammation and insulin resistance
[24-28]. ER stress, besides inducing the expression of pro-
inflammatory cytokines, is also a source of reactive oxy-
gen species, which stimulates pro-inflammatory mediators
[24]. Additionally, excess energy supply to mitochondria
leads to oxidative stress by uncoupling of the electron
chain with release of superoxide [29], a pro-inflammatory
event producing an adverse metabolic outcome not only
in terms of insulin resistance, but perhaps also in terms of
beta cells function [30].
The increased risk for main exposures after addition of
leptin to the models merits interpretation. This adipokine
has known actions which protect against the development
diabetes [31], but its levels are markedly increased in
obese subjects, presumably in part to compensate for the
state of leptin resistance. In previous analyses, we have
shown that leptin is a major risk factor for diabetes in
minimally adjusted models, yet appears as a protective fac-
tor after adjustment for adiposity, inflammation markers
and insulin [11]. Here, we appear to be witnessing a simi-
lar phenomenon - the addition of leptin to our adiposity-
diabetes analyses reveals a concomitant risk due to leptin
resistance. As leptin resistance is strongly correlated with
adiposity, the increases seen in the risk measures of adi-
posity appear to be reflecting this concomitant risk. That
the increase in risk seen for adiposity was more pro-
nounced when associations had been previously adjusted
for insulin (Table 3) may reflect a greater adjustment for
leptin resistance. These variations in relative risk suggest
that leptin resistance is an additional important mediator
of obesity’s risk, an important question for future epidemi-
ologic investigation.
The role of the additional risk factors – hypertension,
non-esterified fatty acids, triglycerides and HDL – in
diabetes causation, and thus in confounding or mediating
associations seen with the above-mentioned factors, is less
clear. Hypertension, as mentioned above, could result, in
part, from chronic vasoconstriction caused by adipokine-
induced, inflammation-mediated endothelial dysfunction,
which in parallel leads to insulin resistance and diabetes.
Increased production of angiotensinogen by inflamed
adipose tissue is another possible mechanism [32]. Within
this context, the decrease in association seen with the
addition of hypertension could be seen as marking
adipokine mediation of the obesity association. The pat-
tern of high NEFA, high triglyceride with low HDL is
characteristic of inflammation, and may be anothermanifestation of chronic low grade inflammation. Higher
NEFA may cause peripheral insulin resistance by interfer-
ing with the access of insulin to skeletal muscle or inter-
fering with insulin signaling resulting in reduced glucose
transport into muscle; in the liver, high levels lead to ex-
cessive endogenous glucose production [33]. In ARIC
Study, NEFA was an independent predictor of diabetes
[34], and could thus play a mediating role. Our results
suggest that processes associated with these factors con-
tribute only minimally, at least for the obesity risk, once
insulin has been taken into account.
Our study has some limitations. First, the fact that vari-
ables that could be considered potential mediators in this
analysis (e.g., adipokines and inflammation markers) were
measured at the same moment as the main exposure
(obesity) limits our ability to test hypotheses regarding
mediation with more sophisticated techniques [35]. None-
theless, we believe that demonstration of changes in effect
measures using a traditional regression approach [36,37]
can advance current knowledge at a population level, and
may stimulate investigations in datasets with multiple
assessments of these factors across time and the em-
ployment of more sophisticated modeling techniques.
Second, selection bias, either due to participants not
returning for follow-up, not having a sample available
for measurement, or exclusion of those participants with
cardiovascular disease, could conceivably have influenced
our results. However, we have little a priori reason to be-
lieve that the associations here demonstrated should be
stronger or weaker among them. Third, our analyses were
based only on fasting samples, and we may not have fully
captured the effects of adipokines and inflammation in the
postprandial period [23]. If so, our findings might under-
estimate the size of the reduction in associations reported.
The resultant residual confounding might account for
some of the remaining risk attributable to obesity in the
final model. Fourth, errors in measurements of different
analytes may have influenced our results. In this regard,
fasting insulin is an imperfect proxy for insulin resistance.
Insulin resistance, along with beta cells failure, is be-
lieved to be a major final common pathway from obesity
to type 2 diabetes. The reduction in obesity-diabetes rela-
tive risk seen with adjustment for insulin is consistent
with this view. The fact that markers of chronic inflamma-
tion led to a similar relative risk reduction, suggests a
major, if not nearly equivalent role for inflammatory path-
ways in the causation of type 2 diabetes.
Our interpretation of these analyses should not be con-
strued as suggesting a linear pathway (nor multiple linear
pathways) from obesity to type 2 diabetes. Undoubtedly
the process is a much more complex one, with various
processes manifesting along the causal pathways, includ-
ing, among them, inflammation and insulin resistance/
beta cells failure. Given the integration of these processes
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ition of what comes first is difficult to address epidemio-
logically and may not be the most relevant question.
Population approaches, such as Mendelian randomization,
particularly when investigating upstream inflammatory
mediators, may complement basic science research in
further elucidating the role of chronic inflammation in
the progression from obesity to type 2 diabetes [38].
The further elucidation of interactions of inflammatory
processes with insulin resistance/beta cells failure, as
well as with additional factors of the metabolic syn-
drome, should advance our understanding of the causes
of current epidemic of type 2 diabetes.
Conclusions
Our findings, when coupled with the literature, support a
major role of adiponectin and other inflammatory factors in
mediating the progression from obesity to type 2 diabetes.
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